✦ LIBER ✦

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

✍ Scribed by Lawitz, Eric; Sulkowski, Mark S; Ghalib, Reem; Rodriguez-Torres, Maribel; Younossi, Zobair M; Corregidor, Ana; DeJesus, Edwin; Pearlman, Brian; Rabinovitz, Mordechai; Gitlin, Norman; Lim, Joseph K; Pockros, Paul J; Scott, John D; Fevery, Bart; Lambrecht, Tom; Ouwerkerk-Mahadevan, Sivi; Callewaert, Katleen; Symonds, William T; Picchio, Gaston; Lindsay, Karen L; Beumont, Maria; Jacobson, Ira M

Book ID: 126222809
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 555 KB
Volume: 384
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(14)61036-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Jacobson, Ira M; Dore, Gregory J; Foster, Graham R; Fried, Michael W; Radu, Moni 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 284 KB

Phase 1b study of pegylated interferon l

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

✍ Andrew J. Muir; Mitchell L. Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 678 KB

Interferon lambda 1 (IFN-k1) is a type III IFN that produces intracellular responses similar to those of IFN-a but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile. This was an open-label three-part study

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

✍ Manns, Michael; Marcellin, Patrick; Poordad, Fred; de Araujo, Evaldo Stanislau A 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 287 KB

P.279 A randomised trial of pegylated in

P.279 A randomised trial of pegylated interferon alpha-2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

✍ A. Ciancio; A. Picciotto; C. Giordanino; A. Smedile; M. Tabone; A. Manca; G. Mar 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 138 KB

A randomized trial of pegylated-interfer

A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

✍ A. CIANCIO; A. PICCIOTTO; C. GIORDANINO; A. SMEDILE; M. TABONE; A. MANCA; G. MAR 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB

Sofosbuvir with pegylated interferon alf

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

✍ Kowdley, Kris V; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 241 KB